PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
0.75%
Positive ROE while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would see if the firm holds a competitive advantage in a struggling sector.
0.56%
Positive ROA while Drug Manufacturers - Specialty & Generic median is negative. Philip Fisher would see if the firm has a stronger model than peers.
-1.31%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is -0.38%. Seth Klarman would investigate whether a turnaround is viable.
15.82%
Gross margin below 50% of Drug Manufacturers - Specialty & Generic median of 48.25%. Jim Chanos would suspect flawed products or pricing.
-51.81%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for a path to operational turnaround.
23.63%
Positive net margin while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might view this as an advantage over struggling peers.